Xi'an Faithful BioTech Co., Ltd. is selling Tirzepatide Raw Powder. Please feel free to contact us if you have any purchase needs.
Send your Inquiry for more details, Click email：sales4@faithfulbio.com
I. Core Understanding: Innovative Molecular Characteristics and Mechanism of Action of Tirzepatide
Tirzepatide is the world's first and currently only clinically applied GLP-1/GIP dual receptor co-agonist. Its molecular design and mechanism of action represent a breakthrough in the industry, setting a benchmark for the development of similar products.
1. Molecular Structure and Modification Technology
Structurally, Tirzepatide is a linear peptide compound composed of 39 amino acids, with the molecular formula C₁₈₇H₂₉₁N₄₅O₅₉. Its amino acid sequence is based on human GIP (glucose-dependent insulinotropic peptide), retaining 9 homologous amino acids of GIP and 10 amino acids shared by GIP and GLP-1 (glucagon-like peptide-1). Through structural modification, it achieves the dual goals of long-lasting effect and high activity. The core modification technology includes two aspects: first, the alanine at position 8 is replaced with α-aminoisobutyric acid (Aib), effectively resisting degradation by dipeptidyl peptidase-4 (DPP-4) and prolonging the product's duration of action in vivo; second, a C-18 alkyl diacid side chain is attached to the C-terminus, significantly enhancing the product's binding affinity to plasma albumin.
Regarding the synthesis process, Tirzepatide employs a combined "solid-phase synthesis + liquid-phase splicing" technique. First, four short peptide fragments (AA1-14, AA15-21, AA22-29, and AA30-39) are prepared using solid-phase synthesis, and then the fragments are linked together using liquid-phase synthesis to form the final product. Compared to the traditional method of sequential coupling of all amino acids, this process reduces amino acid usage by more than 30%, lowers impurity formation rates, and simultaneously improves production efficiency and product purity, laying the foundation for large-scale commercial production.
2. Dual-Target Mechanism of Action and Synergistic Advantages
The core pathological mechanisms of metabolic diseases involve multiple aspects, including insulin resistance, glucagon secretion disorders, and appetite regulation imbalances. Traditional single-target products often struggle to achieve comprehensive regulation. Tirzepatide's revolutionary breakthrough lies in simultaneously activating two major incretin receptors, GLP-1 and GIP, achieving multi-dimensional metabolic improvement through synergistic effects.
GLP-1 receptor agonists have long been proven valuable in the treatment of metabolic diseases, achieving blood sugar reduction and weight loss through promoting insulin secretion, inhibiting glucagon release, delaying gastric emptying, and suppressing central appetite. GIP, another important incretin, can stimulate insulin secretion and regulate lipid metabolism in healthy individuals, but its activity is significantly reduced in patients with type 2 diabetes. Tirzepatide, by precisely activating GIP receptors, can not only restore the physiological function of GIP in patients, but also produce a synergistic effect with the activation of GLP-1 receptors: on the one hand, it enhances the sensitivity and sustainability of insulin secretion, achieving more stable blood sugar control; on the other hand, it accelerates fat breakdown and energy consumption, improving weight loss; at the same time, it can also improve vascular endothelial function and reduce the risk of cardiovascular disease.
Send your Inquiry for more details, Click email：sales4@faithfulbio.com
II. Research and Commercialization: A Decade-Long Journey from Technological Breakthrough to Global Launch
1. Key R&D Milestones
The development of Tirzepatide began in 2010. Based on in-depth research into the incretin signaling pathway, scientists proposed the innovative concept of "dual-target synergistic regulation," breaking through the efficacy bottleneck of single-target products. From 2010 to 2015, the R&D team completed molecular design, structural optimization, and pre-clinical studies, solving the selectivity problem of dual-target activation and confirming the product's safety and efficacy. In 2016, Tirzepatide officially entered the clinical stage, initiating the SURPASS series of global multicenter clinical trials, covering 12,000 patients with type 2 diabetes in multiple countries and regions worldwide, comprehensively evaluating its glycemic efficacy, safety, and cardiovascular benefits. In 2021, the results of the SURPASS series trials were released, showing that its HbA1c reduction reached 2.0%-2.5%, with significant weight loss effects, while also demonstrating good cardiovascular safety, laying a core foundation for subsequent approval.
In the approval and market launch process, Tirzepatide exhibited rapid progress: In May 2022, the US FDA first approved it for the treatment of type 2 diabetes; in November 2023, the FDA approved it for obesity; in May 2024, the China National Medical Products Administration (NMPA) approved it for diabetes, and in July of the same year, it expanded to include obesity, priced at 890 yuan per vial (1.5mg), officially entering the Chinese market; by the end of 2025, Tirzepatide had been approved in more than 100 countries and regions worldwide, covering the two core indications of diabetes and obesity, becoming one of the core products in the global metabolic disease treatment field.
III. Market Structure: Explosive Growth and Duopoly Competition
Since its launch, Tirzepatide has achieved explosive market growth due to its excellent efficacy and broad indications, quickly becoming a core revenue pillar for the company. It has also formed a duopoly with Semaglutide, dominating the development direction of the global GLP-1 product market.
1. Global Market Performance: A Blockbuster
Tirzepatide's market performance has created a miracle of growth for an innovative product since its launch. In its first year on the market in 2022, its global sales reached $5.339 billion, far exceeding the first-year sales of other innovative products during the same period; in 2023, sales exceeded $10 billion, reaching $10.85 billion; and in 2024, it achieved a leapfrog growth, with global sales reaching $16.4458 billion, of which the sugar-lowering version sold $11.5401 billion and the weight-loss version sold $4.9257 billion, accounting for 36% of the company's total revenue, making it one of the most explosive innovative products globally.
In terms of regional distribution, North America is Tirzepatide's core market, accounting for 65% of global sales (mainly the United States), primarily due to its mature healthcare payment system and large patient population with metabolic diseases. The European market accounts for approximately 20%, showing steady growth. While the Chinese market started later (listed in 2024), it has seen the fastest growth, with a compound annual growth rate of 45%. In 2024, sales in the Chinese market exceeded $1.5 billion, becoming one of the core engines of global growth. In the first three quarters of 2025, Tirzepatide's global sales reached $24.837 billion, roughly on par with Semaglutide. According to Bloomberg's forecast, Tirzepatide will surpass Semaglutide in 2026, achieving sales of $40.8 billion, and the gap will continue to widen thereafter, with sales projected to reach $56.8 billion by 2029, making it a true "global king."
2. Competitive Landscape: Duopoly Dominates While Generic Drugs Challenge
The current global GLP-1 product market is characterized by a duopoly, with Tirzepatide and Semaglutide together holding 88% of the global market share, making it difficult for other companies to challenge their leading position. The core competition between the two products focuses on four dimensions: efficacy, indications, price, and distribution channels. In terms of efficacy, Tirzepatide is slightly better than Semaglutide in terms of weight loss and cardiovascular protection, but Semaglutide has a significant first-mover advantage. Regarding indications, both cover diabetes and obesity, but Tirzepatide has made faster progress in potential indications such as obstructive sleep apnea (OSA) and heart failure with preserved ejection fraction (HFpEF). In terms of price, with inclusion in China's medical insurance program, Tirzepatide's price has been significantly reduced, with some specifications pre-sold for as low as 450 yuan, gradually narrowing the price gap with Semaglutide. In terms of distribution channels, both are accelerating their expansion into online platforms (Meituan, JD.com, etc.) to improve product accessibility through the O2O model. Tirzepatide's online order volume increased more than tenfold month-on-month after the price reduction, demonstrating strong price elasticity.
Besides direct competition with Semaglutide, Tirzepatide will also face challenges from generic and biosimilar products in the future. From a patent perspective, Tirzepatide's US patent protection expires in 2036, and its Chinese patent protection expires in 2035, making its patent barrier more robust compared to Semaglutide (whose Chinese patent expires in 2026). However, several companies globally have already begun developing generic versions of Tirzepatide, and the price of these generic products may drop to 20% of the original price, impacting the original market share. Furthermore, the development of multi-target products (such as GLP-1/GIP/GCGR tri-target agonists) is accelerating, with some candidate products already showing weight-loss effects approaching those of Tirzepatide, potentially reshaping the market competition landscape.
Conclusion
Tirzepatide's success lies not only in its groundbreaking clinical efficacy but also in its pioneering dual-target mechanism of action, providing a novel solution for the treatment of metabolic diseases and ushering in a new era of "dual-target/multi-target agonists." From an industry value perspective, Tirzepatide has not only driven explosive growth in the GLP-1 product market but also spurred upgrades in peptide synthesis and formulation technologies, promoting the improvement and development of the industry chain and making significant contributions to the global prevention and control of metabolic diseases.
In the future, with the continuous expansion of indications, ongoing technological upgrades, and penetration into emerging markets, Tirzepatide is expected to maintain its market leadership and become one of the world's highest-selling innovative products. However, it will also face multiple challenges, including policy regulation, market competition, and industry chain fluctuations, requiring related companies to actively address these challenges through technological innovation, cost control, and channel optimization. For industry practitioners, Tirzepatide's development trajectory provides valuable experience for innovative product research and development and commercialization, and its future development trends will provide important reference for industry layout, driving continuous progress in the global field of metabolic disease treatment.
As a provider of premium Tirzepatide CAS 2023788-19-2, Xi'an Faithful BioTech Co., Ltd. leverages state-of-the-art production technology and rigorous quality assurance to meet international pharmaceutical requirements. Our dedication to superior quality, cost-effective pricing, and tailored technical support has made us the preferred collaborator for healthcare professionals and researchers worldwide. To obtain detailed specifications and application guidance for our Tirzepatide Powder, contact our technical team at sales4@faithfulbio.com and explore how our offerings can enhance your product formulations.